Avutometinib Potassium (Ojjaara): Patient Guide
Avutometinib potassium is a prescription targeted therapy for symptomatic plexiform neurofibromas, which are tumor growths associated with neurofibromatosis type 1 (NF1). It is taken by mouth and is approved for adults and children 2 years of age and older.
Avutometinib potassium may help shrink or relieve symptoms of NF1-related plexiform neurofibromas. Take it exactly as prescribed and contact your doctor or pharmacist about side effects, pregnancy, and other medicines.
Key facts at a glance
- RxNorm
- 2714514
- Generic
- Avutometinib Potassium
- Class
- pin-variant
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks to the fetus
regular fetal monitoring via ultrasound
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; consider timing of delivery
regular fetal monitoring and biophysical profiles
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid
discontinue breastfeeding during treatment and for at least 2 weeks after last dose
N/A
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
children under 12safety and efficacy not established
use only in clinical trials or if benefits outweigh potential risks
close monitoring for growth and development
pediatric_age
adolescents 12 17use with caution
use only if potential benefits outweigh risks; monitor growth plates
regular assessment of growth and skeletal development
Use with caution and monitor for adverse effects.
geriatric
elderly over 65no specific dose adjustment required; start at lower end of dosing range
use with caution; monitor for adverse effects including fatigue and GI symptoms
regular monitoring of renal and hepatic function
Use with caution and monitor for adverse effects.
renal_impairment
mildno adjustment needed
monitor renal function periodically
baseline and periodic creatinine clearance monitoring
Use with caution and monitor for adverse effects.
renal_impairment
moderateconsider dose reduction
use with caution; consider dose reduction based on tolerability
close monitoring of renal function and drug tolerability
Use with caution and monitor for adverse effects.
hepatic_impairment
mildno adjustment needed
use with caution; monitor liver enzymes
baseline and periodic liver function tests
Use with caution and monitor for adverse effects.
hepatic_impairment
moderateconsider dose reduction
use with caution; dose reduction may be required
frequent monitoring of liver function and bilirubin
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Avutometinib is a mitogen-activated extracellular signal-regulated kinase kinase (MEK) inhibitor
Development status
Avutometinib Potassium is currently in clinical trials and not yet FDA approved
Mechanism of action
Inhibits MEK1/2 kinase activity to block RAS/RAF/MEK/ERK signaling pathway
Primary investigation area
Being studied for treatment of various solid tumors including pancreatic, ovarian, and lung cancers
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy